Terbinafine Dosing for Tinea Corporis
For tinea corporis, use oral terbinafine 250 mg once daily for 2-4 weeks in adults (>40 kg), with weight-based dosing for children: 62.5 mg/day for <20 kg and 125 mg/day for 20-40 kg.
Important Context: These Guidelines Are for Tinea Capitis
I must clarify that the primary guideline evidence provided 1 addresses tinea capitis (scalp ringworm), not tinea corporis (body ringworm). The dosing recommendations from these British Association of Dermatologists guidelines specifically state treatment durations of 2-4 weeks for tinea capitis, which requires systemic therapy because topical agents cannot penetrate hair follicles.
Recommended Dosing for Tinea Corporis
Adults and Children >40 kg:
- 250 mg once daily for 2-4 weeks 1
Children 20-40 kg:
- 125 mg once daily for 2-4 weeks 1
Children <20 kg:
- 62.5 mg once daily for 2-4 weeks 1
Treatment Duration Considerations
Research evidence supports even shorter treatment courses for tinea corporis specifically:
- 1-week therapy (250 mg daily for 7 days) achieved complete clinical and mycological cure in all patients with tinea corporis/cruris at 6-week follow-up 2
- 2-3 day therapy showed 47-67% mycological cure rates at 2 weeks, though this is less reliable 3
The fungicidal mechanism of terbinafine allows for continued improvement after treatment cessation due to residual tissue effects 4.
Critical Caveats and Pitfalls
Emerging Resistance Issues:
Recent evidence reveals terbinafine-resistant dermatophytes are spreading globally, particularly:
- Trichophyton mentagrophytes genotype VIII from India 5
- Trichophyton rubrum with SQLE gene mutations 6
These resistant strains may require:
- Prolonged therapy with alternative agents (itraconazole, voriconazole)
- Specialized resistance testing if treatment fails
When Standard Dosing Fails:
A 2023 study showed that doubling the dose to 500 mg daily provided no additional benefit over 250 mg for tinea corporis/cruris, with poor overall cure rates (20-33%) at 4 weeks 7. This suggests resistance rather than inadequate dosing when treatment fails.
FDA-Approved Indication:
The FDA label 8 only approves terbinafine for onychomycosis (6 weeks for fingernails, 12 weeks for toenails), not tinea corporis. Use for tinea corporis is off-label but well-established in clinical practice.
Monitoring Requirements
Before initiating therapy 8:
- Obtain baseline liver function tests (ALT, AST) - liver failure can occur
- Warn patients about potential taste/smell disturbances (may be permanent)
- Screen for depressive symptoms during treatment
- Avoid in pregnancy and caution with breastfeeding
Alternative Approach
For limited tinea corporis, topical therapy alone is often sufficient and avoids systemic side effects. Reserve oral terbinafine for:
- Extensive disease
- Failed topical therapy
- Immunocompromised patients
- Involvement of hair follicles 9